Views & Analysis ASCO 2017: Breast cancer next target for Keytruda Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.
Patients ASCO 2026: Quality of life, not just quantity, with Dr Harol... Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.